Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: Propensity score analyses

Journal of Cardiac Failure

Volumn 21, Issue 5, 2015, Pages 391-397

  Isogai, Toshiaki ^a,b   Yasunaga, Hideo ^a   Matsui, Hiroki ^a   Tanaka, Hiroyuki ^b   Horiguchi, Hiromasa ^c   Fushimi, Kiyohide ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Fulminant myocarditis; immunoglobulin propensity; mortality; score analysis

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; CATECHOLAMINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PHOSPHODIESTERASE III INHIBITOR; IMMUNOLOGIC FACTOR;

ADOLESCENT; AGED; ARTICLE; ASSISTED CIRCULATION; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; DRUG COST; DRUG MEGADOSE; EXTRACORPOREAL OXYGENATION; FEMALE; FULMINANT MYOCARDITIS; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; INTRAAORTIC BALLOON PUMP; JAPAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; PRIORITY JOURNAL; PROPENSITY SCORE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; VENTRICULAR ASSIST DEVICE; ADULT; FACTUAL DATABASE; HOSPITAL MORTALITY; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITAL MORTALITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; JAPAN; MALE; MIDDLE AGED; MYOCARDITIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929024947     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.01.004     Document Type: Article

References (39)

1. L.T. Cooper Jr. Myocarditis N Engl J Med 360 2009 1526 1538
2. E.B. Lieberman, G.M. Hutchins, A. Herskowitz, N.R. Rose, and K.L. Baughman Clinicopathologic description of myocarditis J Am Coll Cardiol 18 1991 1617 1626
3. Y. Asaumi, S. Yasuda, I. Morii, H. Kakuchi, Y. Otsuka, and A. Kawamura Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation Eur Heart J 26 2005 2185 2192
4. K.H. Hsu, N.H. Chi, H.Y. Yu, C.H. Wang, S.C. Huang, and S.S. Wang Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center's experience Eur J Cardiothorac Surg 40 2011 682 688
5. N. Aoyama, T. Izumi, K. Hiramori, M. Isobe, M. Kawana, and M. Hiroe National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee) Circ J 66 2002 133 144
6. M. Mirabel, C.E. Luyt, P. Leprince, J.L. Trouillet, P. Leger, and A. Pavie Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support Crit Care Med 39 2011 1029 1035
7. R. Cheng, R. Hachamovitch, M. Kittleson, J. Patel, F. Arabia, and J. Moriguchi Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: a weighted meta-analysis of 170 patients J Card Fail 20 2014 400 406
8. M.A. Acker Mechanical circulatory support for patients with acute-fulminant myocarditis Ann Thorac Surg 71 2001 S73 S76
9. J.L. Peura, M. Colvin-Adams, G.S. Francis, K.L. Grady, T.M. Hoffman, and M. Jessup Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association Circulation 126 2012 2648 2667
10. R.E. McCarthy 3rd, J.P. Boehmer, R.H. Hruban, G.M. Hutchins, E.K. Kasper, and J. Hare Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis N Engl J Med 342 2000 690 695
11. F.S. Rosen Putative mechanisms of the effect of intravenous gamma-globulin Clin Immunol Immunopathol 67 1993 S41 S43
12. H. Takada, C. Kishimoto, and Y. Hiraoka Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus b3 model. Antiviral and anti-inflammatory effects Circulation 92 1995 1604 1611
13. C. Kishimoto, N. Takamatsu, H. Kawamata, H. Shinohara, and H. Ochiai Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change J Am Coll Cardiol 36 2000 1979 1984
14. N.A. Drucker, S.D. Colan, A.B. Lewis, A.S. Beiser, D.L. Wessel, and M. Takahashi Gamma-globulin treatment of acute myocarditis in the pediatric population Circulation 89 1994 252 257
15. D.M. McNamara, W.D. Rosenblum, K.M. Janosko, M.K. Trost, F.S. Villaneuva, and A.J. Demetris Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy Circulation 95 1997 2476 2478
16. D.M. McNamara, R. Holubkov, R.C. Starling, G.W. Dec, E. Loh, and G. Torre-Amione Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy Circulation 103 2001 2254 2259
17. J.L. Robinson, L. Hartling, E. Crumley, B. Vandermeer, and T.P. Klassen A systematic review of intravenous gamma globulin for therapy of acute myocarditis BMC Cardiovasc Disord 5 2005 12
18. I. Kindermann, C. Barth, F. Mahfoud, C. Ukena, M. Lenski, and A. Yilmaz Update on myocarditis J Am Coll Cardiol 59 2012 779 792
19. S. Sagar, P.P. Liu, and L.T. Cooper Jr. Myocarditis Lancet 379 2012 738 747
20. B. Maisch, and S. Pankuweit Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives Heart Fail Rev 18 2013 761 795
21. J.G. Howlett, R.S. McKelvie, J.M. Arnold, J. Costigan, P. Dorian, and A. Ducharme Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials Can J Cardiol 25 2009 85 105
22. A.L. Caforio, S. Pankuweit, E. Arbustini, C. Basso, J. Gimeno-Blanes, and S.B. Felix Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 34 2013 2636 2648
23. JCS Joint Working Group Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version Circ J 75 2011 734 743
24. S. Goland, L.S. Czer, R.J. Siegel, S. Tabak, S. Jordan, and D. Luthringer Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature Can J Cardiol 24 2008 571 574
25. S. Kato, S. Morimoto, S. Hiramitsu, A. Uemura, M. Ohtsuki, and Y. Kato Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis Heart Vessels 22 2007 48 51
26. H.S. Kim, S. Sohn, J.Y. Park, and J.W. Seo Fulminant myocarditis successfully treated with high-dose immunoglobulin Int J Cardiol 96 2004 485 486
27. M. Sumitani, K. Uchida, H. Yasunaga, H. Horiguchi, Y. Kusakabe, and S. Matsuda Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database Anesthesiology 114 2011 84 90
28. P.R. Rosenbaum, and D.B. Rubin Constructing a control group using multivariate matched sampling methods that incorporate the propensity score Am Stat 39 1985 33 38
29. S. Xu, C. Ross, M.A. Raebel, S. Shetterly, C. Blanchette, and D. Smith Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals Value Health 13 2010 273 277
30. T. Nakatani Heart transplantation Circ J 73 2009 A55 A60
31. J.W. Newburger, S.P. Sanders, J.C. Burns, I.A. Parness, A.S. Beiser, and S.D. Colan Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin Circulation 79 1989 1237 1246
32. J.W. Newburger, M. Takahashi, J.C. Burns, A.S. Beiser, K.J. Chung, and C.E. Duffy The treatment of Kawasaki syndrome with intravenous gamma globulin N Engl J Med 315 1986 341 347
33. C. Kishimoto, K. Shioji, T. Hashimoto, H. Nonogi, J.D. Lee, and S. Kato Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance Heart Vessels 29 2014 336 342
34. D.Q. Yu, Y. Wang, G.Z. Ma, R.H. Xu, Z.X. Cai, and C.M. Ni Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: a retrospective study Exp Ther Med 7 2014 97 102
35. L.T. Cooper, K.L. Baughman, A.M. Feldman, A. Frustaci, M. Jessup, and U. Kuhl The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Circulation 116 2007 2216 2233
36. O. Leone, J.P. Veinot, A. Angelini, U.T. Baandrup, C. Basso, and G. Berry 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology Cardiovasc Pathol 21 2012 245 274
37. M. Holzmann, A. Nicko, U. Kühl, M. Noutsias, W. Poller, and W. Hoffmann Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period Circulation 118 2008 1722 1728
38. A. Yilmaz, I. Kindermann, M. Kindermann, F. Mahfoud, C. Ukena, and A. Athanasiadis Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance Circulation 122 2010 900 909
39. C. Chimenti, and A. Frustaci Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period Circulation 128 2013 1531 1541